The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine

Yair Herishanu, Michael Lishner, Yona Kitay-Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. Avery rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid. [

Original languageEnglish
Pages (from-to)177-179
Number of pages3
JournalAnti-Cancer Drugs
Volume13
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Dacarbazine
  • Fulminant hepatitis
  • Steroids

Fingerprint

Dive into the research topics of 'The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine'. Together they form a unique fingerprint.

Cite this